News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start Arkiv för Jakob Ivarsson

Press releases

March 26, 2019

PledPharma will be presenting company’s drug development programs at today’s CMD in Stockholm

March 26, 2019

Data from the POP study support further development of Aladote® as a new treatment option for reducing liver damage due to paracetamol overdose

March 18, 2019

PledPharma’s drug candidate Aladote® granted Orphan Drug Designation

March 14, 2019

PledPharma Capital Markets Day, March 26

February 21, 2019

Year-end Report January-December 2018

February 11, 2019

Helene Depui Ekdal new Clinical Development Director

February 5, 2019

PledPharma Capital Markets Day

January 31, 2019

Aladote®’s data has been selected for presentation at The International Liver Congress

January 17, 2019

PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium

December 24, 2018

PledPharma applies for an Orphan Drug Designation in the US for its life saving drug candidate Aladote

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com